All News
Dr. J. Walsh slide on PROs in PsA research. #ACR20 @RheumNow https://t.co/v4ufUdWufB
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/longer symptom duration & more joint dz and were less likely to be + HLA-B27 than men. Do you see this in your practice? #ABS0876 #ACR20 @RheumNow https://t.co/2goek1NiUW https://t.co/Uk8pmNP4Hr
Dr. Rachel Tate uptoTate ( View Tweet)
Patients with ARDs have incr. susceptibility to #infection. Real-world study shows suboptimal #influenza, #pneumococcal & #herpeszoster #vaccination coverage in these patients. Important to consider strategies to improve uptake.
Abs#0541 #ACR20 @RheumNow
https://t.co/GAapkzILvW
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0
Richard Conway RichardPAConway ( View Tweet)
Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20
Eric Dein ejdein1 ( View Tweet)
Dr Vargas-Santos reported on risk of gout with SGLT2-inhibitors using THIN database. Canagliflozin shown in prior RCT to reduce gout risk. Here dapagliflozin and empagliflozin showed even stronger effect @rheumnow #ACR20 Abstr#660 https://t.co/MTjByMmHo7
Richard Conway RichardPAConway ( View Tweet)
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months).
Prospective, observational study.
@RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Richard Conway RichardPAConway ( View Tweet)
#ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowing precedes erosive disease and requires more attention for early recognition. https://t.co/JLd3xVTlXM
Eric Dein ejdein1 ( View Tweet)
FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox
Dr. Rachel Tate uptoTate ( View Tweet)
Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk.
#RheumTwitter Abs#0540 #ACR20 @RheumNow
https://t.co/kOSToCljeq
Mrinalini Dey DrMiniDey ( View Tweet)
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
Dr McCormick reports sequential patterns of gout flare from the Boston Online Gout Study. Second attack most likely to affect ipsilateral same joint, and second most likely contralateral same joint. @rheumnow #ACR20 Abstr#672 https://t.co/2AAMvcOCk8
Richard Conway RichardPAConway ( View Tweet)
CORRONA: Majority of PsA pts who initiated an advanced therapy had mild to moderate skin involvement. Decision to change therapy w/ rheumatologist based mainly on MSK symptoms. #ABS0873 #ACR20 @RheumNow https://t.co/mOXg5B7goI https://t.co/mqddMYQ3i0
Dr. Rachel Tate uptoTate ( View Tweet)
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Eric Dein ejdein1 ( View Tweet)
Get the highlights on the opening day of #ACR20. Listen in to faculty reports and overviews. Follow the link below or find us on Apple podcasts under RheumNow Podcast.
https://t.co/qDQzCAHsHi https://t.co/9nM19ZdHQQ
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your ACR IQ? Test your knowledge on Day 1 of the ACR meeting and see where you place on the leaderboard. #ACR20
https://t.co/joteMBHjYl https://t.co/46Mo5n3oSq
Links:
Dr. John Cush RheumNow ( View Tweet)
Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+ pts had more therapeutic benefit vs. HLA-B27- pts.
@RheumNow #ACR20 abs#0885 #ACRbest https://t.co/eD3ZGWxDkX
sheila RHEUMarampa ( View Tweet)